Incyte and J&J racing to reach broader FGFR population

27 September 2019

Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte (Nasdaq: INCY) chief executive Hervé Hoppenot.

Results from the FIGHT-202 trial show the novel therapy’s potential as a later-line option in a rare type of cancer, cholangiocarcinoma. Mr Hoppenot believes the option could also be used to treat a broader patient population, including in bladder cancer.

Discussing the data ahead of its presentation at the European Society of Medical Oncology (ESMO) on Friday, he tells The Pharma Letter: "What we are demonstrating here for the first time, is that with a good FGFR inhibitor, like the one we have, you can provide benefit in a very large number of patients. For 80% of patients there was some form of tumor shrinkage."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK